Clinical trial
International, Multi-center, Prospective, Double Randomized, Open Phase III Study Evaluating Thalidomide/Dexamethasone Versus Melphalan/Prednisone as Induction Therapy and Thalidomide/Interferon-alpha Versus Interferon-alpha as Maintenance Therapy in Newly Diagnosed Patients With Multiple Myeloma
NCT00205751 is registered in ClinicalTrials.gov with Austrian Forum Against Cancer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- International, Multi-center, Prospective, Double Randomized, Open Phase III Study Evaluating Thalidomide/Dexamethasone Versus Melphalan/Prednisone as Induction Therapy and Thalidomide/Interferon-alpha Versus Interferon-alpha as Maintenance Therapy in Newly Diagnosed Patients With Multiple Myeloma
- Lead sponsor
- Austrian Forum Against Cancer
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- August 31, 2001
- Completion date
- October 31, 2009
- Enrollment
- 350 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.